Frazier Life Sciences Acquisition Corp. II (FLSC)
Frazier Life Sciences Acquisition Corp. II will go public soon, but the exact IPO date is still unknown.
IPO Price
$10.00
Shares Offered
7,500,000
Deal Size
$75.00M
Company Description
Frazier Life Sciences Acquisition II is a blank check company incorporated for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
We intend to capitalize on the experience and ability of our management team to identify promising opportunities in the biotechnology sector, with the goal of financing a company that can develop important new therapies for patients while creating value for shareholders.
Frazier Life Sciences Acquisition Corp. II
| Country | United States |
| Founded | 2026 |
| Industry | Shell Companies |
| Sector | Financials |
| CEO | Albert Cha, M.D., Ph.D. |
Contact Details
Address: 1001 Page Mill Road, Building 4, Suite 200B Palo Alto, CA 93404 United States | |
| Phone | (650) 325-5156 |
Stock Details
| Ticker Symbol | FLSC |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 2153598 |
| Employer ID | 98-1964369 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Albert Cha, M.D., Ph.D. | Chief Executive Officer and Director |
| Fran Adams | Chief Financial Officer |
| Kevin Li, M.D. | Chief Business Officer |
| Ali Jackson, J.D. | General Counsel |
| William C. Fairey, Jr. | Director |
| Benjamin L. Palleiko | Director, Chairman |
| R. Scott Struthers, Ph.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 24, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Sep 11, 2026 | DRS | [Cover] Draft Registration Statement |